Citations

Clear

6274 citation(s) found for "To, Andrew".

Targeting CARD9 with Small-Molecule Therapeutics Inhibits Innate Immune Signaling and Inflammatory Response to Pneumocystis carinii β-Glucans
Carmona, Eva M. , Limper, Andrew H. , Kottom, Theodore J. , Limper, Andrew H , Carmona, Eva M

Mayo Clinic

Antimicrobial Agents and Chemotherapy | August 20, 2020 | Volume: 64 | Issue: 11 | Pages: No page available

10.1128/aac.01210-20 | PMID 32839216 Get It

Pneumocystis jirovecii , the opportunistic fungus that causes Pneumocystis pneumonia (PCP) in humans, is a significant contributor to morbidity and mortality in immunocompromised patients. Given the profound deleterious inflammatory effects of the major β-glucan cell wall carbohydrate constituents of Pneumocystis through Dectin-1 engagement and downstream caspase recruitment domain-containing protein 9 (CARD9) immune activation, we sought to determine whether the pharmacodynamic activity of the known CARD9 inhibitor BRD5529 might have a therapeutic effect on macrophage innate immune signaling and subsequent downstream anti-inflammatory activity.
IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405
Guercio, Brendan J. , Zhang, Sui , Ou, Fang‐Shu , Venook, Alan P. , Niedzwiecki, Donna , Lenz, Heinz‐Josef , Innocenti, Federico , Pollak, Michaël , Nixon, Andrew B. , Mullen, Brian C, O’Neil, Bert H. , Polite, Blasé N. , Benson, Al B. , Atkins, James N., Goldberg, Richard M. , Blanke, Charles D. , Fuchs, Charles S. , Meyerhardt, Jeffrey A. , Pollak, Michael N , Goldberg, Richard M , Brown, Justin C , Fuchs, Charles S , Meyerhardt, Jeffrey A , Venook, Alan P , Ou, Fang-Shu , Nixon, Andrew B , Niedzwiecki, Donna , Shaw, James Edward , Brown, Justin C. , O’Reilly, Eileen M. , Mayer, Robert J.

Mayo Clinic

JNCI Cancer Spectrum | August 19, 2020 | Volume: 5 | Issue: 1 | Pages: No page available

10.1093/jncics/pkaa074 | PMID 33426464 Get It

AbstractBackgroundEnergy balance-related biomarkers are associated with risk and prognosis of various malignancies. Their relationship to survival in metastatic colorectal cancer (mCRC) requires further study.MethodsBaseline plasma insulin-like growth factor (IGF)-1, IGF-binding protein (IGFBP)-3, IGFBP-7, C-peptide, and adiponectin were measured at time of trial registration in a prospective cohort of patients with mCRC participating in a National Cancer Institute–sponsored trial of first-line systemic therapy. We used Cox proportional hazards regression to adjust for confounders and examine associations of each biomarker with overall survival (OS) and progression-free survival (PFS). P values are 2-sided.ResultsMedian follow-up for 1086 patients was 6.2 years. Compared with patients in the lowest IGFBP-3 quintile, patients in the highest IGFBP-3 quintile experienced an adjusted hazard ratio (HR) for OS of 0.57 (95% confidence interval [CI] = 0.42 to 0.78; Pnonlinearity < .001) and for PFS of 0.61 (95% CI = 0.45 to 0.82; Ptrend = .003). Compared with patients in the lowest IGFBP-7 quintile, patients in the highest IGFBP-7 quintile experienced an adjusted hazard ratio for OS of 1.60 (95% CI = 1.30 to 1.97; Ptrend < .001) and for PFS of 1.38 (95% CI = 1.13 to 1.69; Ptrend < .001). Plasma C-peptide and IGF-1 were not associated with patient outcomes. Adiponectin was not associated with OS; there was a nonlinear U-shaped association between adiponectin and PFS (Pnonlinearity = .03).ConclusionsAmong patients with mCRC, high plasma IGFBP-3 and low IGFBP-7 were associated with longer OS and PFS. Extreme levels of adiponectin were associated with shorter PFS. These findings suggest potential avenues for prognostic and therapeutic innovation.
Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation–positive acute myeloid leukemia: the RADIUS-X expanded access program
Strickland, Stephen A. , Litzow, Mark R. , Dalovisio, Andrew, Perl, Alexander E. , Bonifacio, Gaetano, Haines, Kelly, Barbera, Alysha, Purkayastha, Das, Sweet, Kendra , Strickland, Stephen Anthony , Litzow, Mark R. , Perl, Alexander E , Roboz, Gail J.

Mayo Clinic

Leukemia & Lymphoma | August 19, 2020 | Volume: 61 | Issue: 13 | Pages: 3146-3153

10.1080/10428194.2020.1805109 | PMID 32812818 Get It

Inference from longitudinal laboratory tests characterizes temporal evolution of COVID-19-associated coagulopathy (CAC)
Pawlowski, Colin , Wagner, Tyler , Puranik, Arjun, Loscalzo, Liam, Pruthi, Rajiv K. , Houghton, Damon E. , O’Horo, John C. , Morice, William G. , Williams, Amy W. , Badley, Andrew D. , Barnathan, Elliot S. , Makimura, Hideo, Khan, Najat, O'Horo, John C, Soundararajan, Venky , Houghton, Damon E , Badley, Andrew D , O'Horo, John C , Murugadoss, Karthik , Venkatakrishnan, A J , Morice, William George , Gores, Gregory J. , Halamka, John , Soundararajan, Venky

Mayo Clinic

eLife | August 17, 2020 | Volume: 9 | Issue: No issue available | Pages: No page available

10.7554/elife.59209 | PMID 32804081 Get It

Temporal inference from laboratory testing results and triangulation with clinical outcomes extracted from unstructured electronic health record (EHR) provider notes is integral to advancing precision medicine. Here, we studied 246 SARS-CoV-2 PCR-positive (COVID pos ) patients and propensity-matched 2460 SARS-CoV-2 PCR-negative (COVID neg ) patients subjected to around 700,000 lab tests cumulatively across 194 assays. Compared to COVID neg patients at the time of diagnostic testing, COVID pos patients tended to have higher plasma fibrinogen levels and lower platelet counts. However, as the infection evolves, COVID pos patients distinctively show declining fibrinogen, increasing platelet counts, and lower white blood cell counts. Augmented curation of EHRs suggests that only a minority of COVID pos patients develop thromboembolism, and rarely, disseminated intravascular coagulopathy (DIC), with patients generally not displaying platelet reductions typical of consumptive coagulopathies. These temporal trends provide fine-grained resolution into COVID-19 associated coagulopathy (CAC) and set the stage for personalizing thromboprophylaxis.
Intake of Dietary Fruit, Vegetables, and Fiber and Risk of Colorectal Cancer According to Molecular Subtypes: A Pooled Analysis of 9 Studies
Hidaka, Akihisa , Harrison, Tabitha A. , Cao, Yin , Sakoda, Lori C. , Barfield, Richard , Giannakis, Marios , Phipps, Amanda I. , Figueiredo, Jane C. , Zaidi, Syed Hassan Ejaz , Berndt, Sonja I. , Borozan, Ivan , Gallinger, Steven , Gunter, Marc J. , Guinter, Mark A. , Harlid, Sophia , Moreno, Vı́ctor , Nishihara, Reiko , Obón‐Santacana, Mireia , Parfrey, Patrick S. , Slattery, Martha L. , Steinfelder, Robert S. , Wang, Xiaoliang , Woods, Michael O. , Guelpen, Bethany Van , Thibodeau, Stephen N. , Hoffmeister, Michael , Peters, Ulrike , Amitay, Efrat L , Guinter, Mark A , Harlid, Sophia , Hampel, Heather , Moreno, Victor , Ogino, Shuji , Potter, John D , Slattery, Martha L , Um, Caroline Y , Van Guelpen, Bethany , Hoffmeister, Michael , Sun, Wei , Buchanan, Daniel D , Sakoda, Lori C , Cao, Yin , Gunter, Marc J , Harrison, Tabitha A , Hidaka, Akihisa , Wang, Xiaoliang , Obón-Santacana, Mireia , Song, Mingyang , Toland, Amanda Ewart , Amitay, Efrat L. , Chan, Andrew T. , Hampel, Heather , Jenkins, Mark A. , Lin, Yi , Newcomb, Polly A. , Potter, John D. , Um, Caroline Y. , Sun, Wei , Hsu, Li , Buchanan, Daniel D. , Campbell, Peter T.

Mayo Clinic

Cancer Research | August 14, 2020 | Volume: 80 | Issue: 20 | Pages: 4578-4590

10.1158/0008-5472.can-20-0168 | PMID 32816852 Get It

Abstract Protective associations of fruits, vegetables, and fiber intake with colorectal cancer risk have been shown in many, but not all epidemiologic studies. One possible reason for study heterogeneity is that dietary factors may have distinct effects by colorectal cancer molecular subtypes. Here, we investigate the association of fruit, vegetables, and fiber intake with four well-established colorectal cancer molecular subtypes separately and in combination. Nine observational studies including 9,592 cases with molecular subtypes for microsatellite instability (MSI), CpG island methylator phenotype (CIMP), and somatic mutations in BRAF and KRAS genes, and 7,869 controls were analyzed. Both case-only logistic regression analyses and polytomous logistic regression analyses (with one control set and multiple case groups) were used. Higher fruit intake was associated with a trend toward decreased risk of BRAF-mutated tumors [OR 4th vs. 1st quartile = 0.82 (95% confidence interval, 0.65–1.04)] but not BRAF-wildtype tumors [1.09 (0.97–1.22); P difference as shown in case-only analysis = 0.02]. This difference was observed in case–control studies and not in cohort studies. Compared with controls, higher fiber intake showed negative association with colorectal cancer risk for cases with microsatellite stable/MSI-low, CIMP-negative, BRAF-wildtype, and KRAS-wildtype tumors (Ptrend range from 0.03 to 3.4e-03), which is consistent with the traditional adenoma-colorectal cancer pathway. These negative associations were stronger compared with MSI-high, CIMP-positive, BRAF-mutated, or KRAS-mutated tumors, but the differences were not statistically significant. These inverse associations for fruit and fiber intake may explain, in part, inconsistent findings between fruit or fiber intake and colorectal cancer risk that have previously been reported. Significance: These analyses by colorectal cancer molecular subtypes potentially explain the inconsistent findings between dietary fruit or fiber intake and overall colorectal cancer risk that have previously been reported.
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
Abida, Wassim , Patnaik, Akash , Campbell, David , Shapiro, Jeremy , Bryce, Alan H. , McDermott, Ray , Sautois, Brieuc , Bambury, Richard , Voog, Éric , Zhang, Jingsong , Piulats, Josep M. , Ryan, Charles J. , Merseburger, Axel S. , Daugaard, Gedske , Heidenreich, Axel , Fizazi, Karim , Higano, Celestia S. , Krieger, Laurence E. , Watkins, Simon P. , Despain, Darrin , Simmons, Andrew D. , Loehr, Andrea , Dowson, Melanie, Golsorkhi, Tony, Chowdhury, Simon, investigators, on behalf of the TRITON2, Bryce, Alan H , Watkins, Simon P , Daugaard, Gedske , McDermott, Ray , Patnaik, Akash , Vogelzang, Nicholas J. , Sternberg, Cora N , investigators, on behalf of the TRITON2

Mayo Clinic

Journal of Clinical Oncology | August 14, 2020 | Volume: 38 | Issue: 32 | Pages: 3763-3772

10.1200/jco.20.01035 | PMID 32795228 Get It

PURPOSE BRCA1 or BRCA2 ( BRCA) alterations are common in men with metastatic castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly(ADP-ribose) polymerase inhibitors. We present results from patients with mCRPC associated with a BRCA alteration treated with rucaparib 600 mg twice daily in the phase II TRITON2 study. METHODS We enrolled patients who progressed after one to two lines of next-generation androgen receptor–directed therapy and one taxane-based chemotherapy for mCRPC. Efficacy and safety populations included patients with a deleterious BRCA alteration who received ≥ 1 dose of rucaparib. Key efficacy end points were objective response rate (ORR; per RECIST/Prostate Cancer Clinical Trials Working Group 3 in patients with measurable disease as assessed by blinded, independent radiology review and by investigators) and locally assessed prostate-specific antigen (PSA) response (≥ 50% decrease from baseline) rate. RESULTS Efficacy and safety populations included 115 patients with a BRCA alteration with or without measurable disease. Confirmed ORRs per independent radiology review and investigator assessment were 43.5% (95% CI, 31.0% to 56.7%; 27 of 62 patients) and 50.8% (95% CI, 38.1% to 63.4%; 33 of 65 patients), respectively. The confirmed PSA response rate was 54.8% (95% CI, 45.2% to 64.1%; 63 of 115 patients). ORRs were similar for patients with a germline or somatic BRCA alteration and for patients with a BRCA1 or BRCA2 alteration, while a higher PSA response rate was observed in patients with a BRCA2 alteration. The most frequent grade ≥ 3 treatment-emergent adverse event was anemia (25.2%; 29 of 115 patients). CONCLUSION Rucaparib has antitumor activity in patients with mCRPC and a deleterious BRCA alteration, but with a manageable safety profile consistent with that reported in other solid tumor types.
Talaromycosis in a renal transplant recipient returning from South China
Vergidis, Paschalis , Rao, Anirudh , Moore, Caroline B. , Rautemaa‐Richardson, Riina , Sweeney, Louise C., Morton, Muir, Johnson, Elizabeth M. , Borman, Andrew M. , Augustine, Titus , Augustine, Titus , Vergidis, Paschalis , Borman, Andrew , Richardson, Malcolm D

Mayo Clinic

Transplant Infectious Disease | August 14, 2020 | Volume: 23 | Issue: 1 | Pages: No page available

10.1111/tid.13447 | PMID 32794335 Get It

AbstractTalaromycosis is a fungal infection endemic in Southeast Asia. We report a case of a renal transplant recipient who developed infection after a trip to South China. She presented with constitutional symptoms and was found to have an FDG‐avid lung mass. Histopathology demonstrated small yeast cells and culture grew Talaromyces marneffei. The patient was treated with 2 weeks of liposomal amphotericin B followed by itraconazole. The dose of tacrolimus was significantly reduced because of the interaction with itraconazole. Mycophenolate mofetil was discontinued. After 12 months of treatment, the mass had completely resolved. Talaromycosis has mainly been reported in patients with AIDS and is uncommon among solid organ transplant recipients. The immune response against T. marneffei infection is mediated predominantly by T cells and macrophages. The diagnosis may not be suspected outside of endemic areas. We propose a therapeutic approach in transplant patients by extrapolating the evidence from the HIV literature and following practices applied to other endemic mycoses.
Hospital discharge hemoglobin values and posthospitalization clinical outcomes in transfused patients undergoing noncardiac surgery
Kerfeld, Mitchell J. , Kor, Daryl J. , Frank, Ryan D. , Hanson, Andrew C. , Passe, Melissa, Warner, Matthew A. , Passe, Melissa A, Warner, Matthew A

Mayo Clinic

Transfusion | August 14, 2020 | Volume: 60 | Issue: 10 | Pages: 2250-2259

10.1111/trf.16002 | PMID 32794229 Get It

AbstractBackgroundRed blood cell (RBC) transfusion is common in surgical patients, yet optimal transfusion targets are incompletely defined in the perioperative period. Hemoglobin levels at the time of hospital discharge may provide insight into transfusion practices, anemia management, and patient outcomes.Study Design and MethodsThis is an observational cohort study of adults receiving RBC transfusion during noncardiac surgery from 2010 to 2014. Multivariable regression was used to assess the relationships between hospital discharge hemoglobin concentrations, anemia severity (severe: <8 g/dL; moderate: 8‐10 g/dL; mild/none: ≥10 g/dL), and clinical outcomes, including a primary outcome of 30‐day hospital readmission and secondary outcomes of posthospitalization RBC transfusion, composite stroke or myocardial infarction, and mortality.ResultsA total of 3129 patients were included: 165 (5%) with severe discharge anemia, 1962 (63%) moderate, and 1002 (32%) with mild/none. Five hundred ninety‐two (19%) were readmitted, with the highest rates observed with severe anemia (26% vs 19% for mild/none). Readmissions were not significantly different after multivariable adjustment (overall P = .216); however, in those receiving postoperative intensive care, severe anemia was associated with increased readmission rates (hazard ratio [HR], 1.72; 95% confidence interval [CI], 1.09‐2.71; reference mild/none]. Posthospitalization RBC transfusion rates were highest with severe anemia (25% vs 10% for mild/none; adjusted HR, 2.2; 95% CI, 1.5‐3.3; P < .001). There were no significant differences in composite stroke/myocardial infarction, or mortality. RBC transfusion volumes did not modify anemia‐outcome relationships.ConclusionHospital discharge hemoglobin values for transfused surgical patients were not associated with hospital readmission rates except for those receiving postoperative intensive care. Further evaluation is warranted to understand downstream consequences of postsurgical anemia.
Sequential Protocol Biopsies Post–Liver Transplant From Donors With Moderate Macrosteatosis: What Happens to the Fat?
Croome, Kristopher P. , Livingston, David H. , Croome, Sarah, Nakhleh, Raouf E. , Croome, Kris P , Livingston, David, Keaveny, Andrew P. , Taner, C. Burcin

Mayo Clinic

Liver Transplantation | August 11, 2020 | Volume: 27 | Issue: 2 | Pages: 248-256

10.1002/lt.25867 | PMID 32779325 Get It

The number of steatotic deceased donor livers encountered has continued to rise as a result of the obesity epidemic. Little is known about the histological characteristics of moderately macrosteatotic livers over time in the recipient following liver transplantation (LT). All recipients undergoing LT at Mayo Clinic Florida with donor livers with moderate macrosteatosis (30%‐60%) from 2000‐2017 were identified (n = 96). Routine protocol liver biopsies were performed 1‐week and 6‐months following LT. All liver donor and protocol biopsies were read by an experienced liver pathologist. Of the 96 moderate macrosteatosis LTs, 70 recipients had post‐LT protocol liver biopsies available and comprised the study cohort. Median donor allograft macrosteatosis at the time of transplant was 33% (IQR, 30%‐40%) compared with 0% (IQR, 0%‐2%) at 1‐week (P < 0.001) and 0% (IQR, 0%‐0%) at 6‐months (P < 0.001) following LT. Biopsies at 1‐week post‐LT displayed pericentral necrosis in 57.1% of recipients and lipopeliosis in 34.3% of recipients. In the 6‐month post‐LT biopsies, cholestasis was seen in 3 (4.3%) of the recipients, whereas grade 2 fibrosis was seen in 6 recipients (8.6%). Graft survival at 5 years in the present cohort was 74.0%. Moderate macrosteatosis (30%‐60%) in the donor allograft demonstrates complete reversal on liver biopsies performed as early as 7 days following LT and remains absent at 6‐months following LT. Both pericentral necrosis and lipopeliosis are common features on day 7 biopsies. Despite these encouraging findings, the perioperative risks of using these livers (postreperfusion cardiac arrest and primary nonfunction) should not be understated. Long‐term graft survival is acceptable in patients who are able to overcome the immediate perioperative risk of using moderately steatotic donor livers.